查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1621310

肉瘤藥物市場：按適應症、按藥物、按銷售管道、按最終用戶分類 - 全球預測 2025-2030

Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

肉瘤治療市場2023年估值為15.4億美元，預計到2024年將達到16.6億美元，複合年成長率為8.10%，到2030年預計將達到26.6億美元。

肉瘤治療藥物市場範圍和定義涵蓋旨在治療肉瘤的藥物治療的開發、生產和分銷，肉瘤是一種影響骨骼和軟組織的罕見且異質性的間質來源腫瘤。迫切需要肉瘤藥物來改善受這一多樣化群體影響的患者的生存和結果，該群體有 50 多種亞型，並且通常具有不同的遺傳觀察。這些藥物的應用包括手術、化療和免疫療法中的新輔助和輔助治療，並且擴大採用創新方法和標靶治療。最終用途範圍主要包括醫院、癌症治療中心和向患者提供這些治療的專科診所。

主要市場統計
基準年[2023] 15.4億美元
預測年份 [2024] 16.6億美元
預測年份 [2030] 26.6億美元
複合年成長率（%） 8.10%

根據市場洞察，關鍵的成長要素包括診斷技術的進步、研發投資的增加以及對肉瘤病理學了解的加深，從而促進新藥的開發。此外，與孤兒藥指定相關的監管優勢，以及醫療保健支出和宣傳宣傳活動，帶來了巨大的商機。公司應該利用精準醫療創新的潛在機會，利用基因和分子分析進行標靶治療。然而，市場受到高昂的治療開發成本、嚴格的監管核准、有限的患者群體（降低了經濟吸引力）以及肉瘤類型的異質性（使臨床試驗和藥物療效複雜化）的限制。

儘管有這些挑戰，創新和研究潛力最大的領域包括免疫腫瘤學、生物相似藥開發和個人化醫療方法。共用研究和開發舉措以及強調促進藥物監管的夥伴關係也可能提供策略優勢。此外，給藥機制和組合治療策略的創新有可能增強患者的反應和治療結果。市場競爭仍然激烈，各公司正專注於併購、聯盟和夥伴關係關係，以加強其產品組合併滿足肉瘤治療方面未滿足的需求。總之，相關人員必須克服複雜的法規，投資於有針對性的研究，並採取策略聯盟以實現市場的永續成長。

市場動態：揭示快速發展的肉瘤藥物市場的關鍵市場洞察

肉瘤藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 肉瘤發生率不斷增加，需要有效的治療方案
    • 政府鼓勵肉瘤治療的努力
    • 政府對改良肉瘤藥物的有利核准
  • 市場限制因素
    • 肉瘤的報銷限制
  • 市場機會
    • 持續研究和開發先進和新型肉瘤療法
    • 改善肉瘤的標靶治療和免疫治療方法
  • 市場挑戰
    • 肉瘤的抗藥性問題

波特五力：駕馭肉瘤藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肉瘤藥物市場的外部影響

外部宏觀環境因素在塑造肉瘤治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解肉瘤治療藥物市場的競爭狀況

對肉瘤治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質肉瘤治療市場供應商的績效評估

FPNV定位矩陣是評估肉瘤治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製肉瘤藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對肉瘤藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肉瘤發生率增加以及有效治療方法的需要
      • 政府鼓勵肉瘤治療的努力
      • 政府對改良肉瘤藥物的有利核准
    • 抑制因素
      • 肉瘤的補償有限
    • 機會
      • 持續研究和開發先進的新肉瘤治療方法
      • 改善肉瘤的標靶治療和免疫治療方法
    • 任務
      • 與肉瘤抗藥性相關的問題
  • 市場區隔分析
    • 適應症：平滑肌肉瘤發生率高，開發新藥值得期待。
    • 製藥：採用標靶肉瘤療法，根據個別基因突變進行更客製化的治療
    • 銷售管道：由於處方藥宅配服務的便利性，線上銷售管道越來越受到青睞。
    • 最終使用者：為醫院和診所不同類型和階段的肉瘤患者提供多種藥物選擇
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章肉瘤藥物市場（按適應症）

  • 血管肉瘤
  • 軟骨肉瘤
  • 隆突性皮膚纖維肉瘤
  • 上皮樣肉瘤
  • 卡波西氏肉瘤
  • 平滑肌肉瘤
  • 脂肪肉瘤
  • 骨癌
  • 軟組織肉瘤

第7章肉瘤藥物治療市場

  • 化療藥物
    • Cisplatin
    • 多西紫杉醇
    • 阿黴素
    • Etoposide
    • Gemcitabine
    • 異環磷醯胺
    • 紫杉醇
    • 曲貝替定
    • 長春新鹼
  • 免疫治療藥物
    • Atezolizumab
    • Pembrolizumab
  • 標靶藥物治療
    • 恩曲替尼
    • Pazopanib
    • Sorafenib
    • Sunitinib
    • Tazemetostat

第8章肉瘤藥物市場：按銷售管道

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第9章肉瘤藥物市場：依最終使用者分類

  • 癌症研究中心
  • 居家護理
  • 醫院/診所

第10章美洲肉瘤藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太肉瘤藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲肉瘤藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 住友製藥腫瘤學獲得治療伊文氏肉瘤的孤兒藥資格
    • FDA核准Atezolizumab用於治療兒科患者的肺泡軟組織肉瘤
    • 美國FDA 授予 Avacta 軟組織肉瘤治療孤兒藥資格
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • AgonOx
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Avacta Life Sciences Limited
  • Baxter International Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • TRACON Pharmaceuticals, Inc.
  • Viatris Inc.
Product Code: MRR-C002B1C996FA

The Sarcoma Drugs Market was valued at USD 1.54 billion in 2023, expected to reach USD 1.66 billion in 2024, and is projected to grow at a CAGR of 8.10%, to USD 2.66 billion by 2030.

The scope and definition of the sarcoma drugs market encompass the development, production, and distribution of pharmaceutical treatments aimed at tackling sarcomas, which are rare and heterogeneous tumors of mesenchymal origin affecting both bone and soft tissues. The necessity of sarcoma drugs arises from the pressing need to improve survival rates and treatment outcomes for patients suffering from this diverse group of over 50 subtypes, often characterized by distinct genetic findings. Application of these drugs includes neoadjuvant and adjuvant therapies in surgery, chemotherapy, and immunotherapy, where innovative approaches and targeted therapies are increasingly adopted. The end-use scope primarily involves hospitals, cancer treatment centers, and specialty clinics, which administer these treatments to patients.

KEY MARKET STATISTICS
Base Year [2023] USD 1.54 billion
Estimated Year [2024] USD 1.66 billion
Forecast Year [2030] USD 2.66 billion
CAGR (%) 8.10%

Market insights reveal that key growth factors include advancements in diagnostic technologies, increased R&D investment, and enhanced understanding of sarcoma pathogenesis leading to novel drug developments. Moreover, regulatory incentives for orphan drug designation foster significant opportunities, along with rising healthcare expenditure and awareness campaigns. Companies should capitalize on the innovation of precision medicine, exploiting genetic and molecular profiling for targeted therapies as a potential opportunity. However, the market faces limitations such as high costs of therapy development, stringent regulatory approvals, limited patient population leading to reduced financial allure, and heterogeneity of sarcoma types, which complicates clinical trials and drug efficacies.

Despite these challenges, the best potential areas for innovation and research include immuno-oncology, development of biosimilars, and personalized medicine approaches. Emphasis on partnerships for shared R&D initiatives and accelerated regulatory pathways may also provide strategic advantages. Furthermore, innovation in delivery mechanisms and combinatorial treatment strategies can enhance patient response and outcomes. The nature of the market remains highly competitive, with companies focusing on mergers and acquisitions, collaborations, and partnerships to strengthen their portfolios and meet the unmet needs in sarcoma treatment. Conclusively, stakeholders must navigate regulatory complexities, invest in targeted research, and adopt strategic collaborations for sustained market growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sarcoma Drugs Market

The Sarcoma Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of sarcoma and the need for effective treatment options
    • Government initiatives encouraging the treatment of sarcoma
    • Favorable government approvals for improved sarcoma drugs
  • Market Restraints
    • Limited reimbursements available for sarcoma
  • Market Opportunities
    • Ongoing research and development for advanced and new sarcoma drugs
    • Improvements in targeted and immunotherapy approaches for sarcoma
  • Market Challenges
    • Issues associated with drug resistance in sarcomas

Porter's Five Forces: A Strategic Tool for Navigating the Sarcoma Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sarcoma Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sarcoma Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sarcoma Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sarcoma Drugs Market

A detailed market share analysis in the Sarcoma Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sarcoma Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sarcoma Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sarcoma Drugs Market

A strategic analysis of the Sarcoma Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sarcoma Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AgonOx, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Avacta Life Sciences Limited, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, TRACON Pharmaceuticals, Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Sarcoma Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans, Epithelioid Sarcoma, Kaposi's Sarcoma, Leiomyosarcoma, Liposarcoma, Osteosarcoma, and Soft Tissue Sarcoma.
  • Based on Drugs, market is studied across Chemotherapy Drugs, Immunotherapy Drugs, and Targeted Drug Therapy. The Chemotherapy Drugs is further studied across Cisplatin, Docetaxel, Doxorubicin, Etoposide, Gemcitabine, Ifosfamide, Paclitaxel, Trabectedin, and Vincristine. The Immunotherapy Drugs is further studied across Atezolizumab and Pembrolizumab. The Targeted Drug Therapy is further studied across Entrectinib, Pazopanib, Sorafenib, Sunitinib, and Tazemetostat.
  • Based on Sales Channel, market is studied across Offline and Online. The Offline is further studied across Hospitals Pharmacies and Retail Pharmacies.
  • Based on End-User, market is studied across Cancer Research Center, Homecare, and Hospital & clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of sarcoma and the need for effective treatment options
      • 5.1.1.2. Government initiatives encouraging the treatment of sarcoma
      • 5.1.1.3. Favorable government approvals for improved sarcoma drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursements available for sarcoma
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for advanced and new sarcoma drugs
      • 5.1.3.2. Improvements in targeted and immunotherapy approaches for sarcoma
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with drug resistance in sarcomas
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication: High incidence rates of leiomyosarcoma encouraging new drug development
    • 5.2.2. Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations
    • 5.2.3. Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications
    • 5.2.4. End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sarcoma Drugs Market, by Indication

  • 6.1. Introduction
  • 6.2. Angiosarcoma
  • 6.3. Chondrosarcoma
  • 6.4. Dermatofibrosarcoma Protuberans
  • 6.5. Epithelioid Sarcoma
  • 6.6. Kaposi's Sarcoma
  • 6.7. Leiomyosarcoma
  • 6.8. Liposarcoma
  • 6.9. Osteosarcoma
  • 6.10. Soft Tissue Sarcoma

7. Sarcoma Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Chemotherapy Drugs
    • 7.2.1. Cisplatin
    • 7.2.2. Docetaxel
    • 7.2.3. Doxorubicin
    • 7.2.4. Etoposide
    • 7.2.5. Gemcitabine
    • 7.2.6. Ifosfamide
    • 7.2.7. Paclitaxel
    • 7.2.8. Trabectedin
    • 7.2.9. Vincristine
  • 7.3. Immunotherapy Drugs
    • 7.3.1. Atezolizumab
    • 7.3.2. Pembrolizumab
  • 7.4. Targeted Drug Therapy
    • 7.4.1. Entrectinib
    • 7.4.2. Pazopanib
    • 7.4.3. Sorafenib
    • 7.4.4. Sunitinib
    • 7.4.5. Tazemetostat

8. Sarcoma Drugs Market, by Sales Channel

  • 8.1. Introduction
  • 8.2. Offline
    • 8.2.1. Hospitals Pharmacies
    • 8.2.2. Retail Pharmacies
  • 8.3. Online

9. Sarcoma Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Cancer Research Center
  • 9.3. Homecare
  • 9.4. Hospital & clinics

10. Americas Sarcoma Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sarcoma Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sarcoma Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment
    • 13.3.2. FDA approves atezolizumab for alveolar soft part sarcoma in pediatric patients
    • 13.3.3. US FDA grants Orphan Drug status to Avacta's drug for soft tissue sarcoma
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AgonOx
  • 4. Amneal Pharmaceuticals LLC
  • 5. Aurobindo Pharma Limited
  • 6. Avacta Life Sciences Limited
  • 7. Baxter International Inc.
  • 8. Bayer AG
  • 9. Bristol-Myers Squibb Company
  • 10. Daiichi Sankyo Company, Limited
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fresenius SE & Co. KGaA
  • 15. GlaxoSmithKline PLC
  • 16. Hikma Pharmaceuticals PLC
  • 17. Ipsen Pharma
  • 18. Johnson & Johnson Services, Inc.
  • 19. Karyopharm Therapeutics Inc.
  • 20. Lupin Limited
  • 21. Merck & Co., Inc.
  • 22. Novartis AG
  • 23. Pfizer Inc.
  • 24. Sumitomo Pharma Co., Ltd.
  • 25. Sun Pharmaceutical Industries Limited
  • 26. TRACON Pharmaceuticals, Inc.
  • 27. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. SARCOMA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. SARCOMA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SARCOMA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 193. THAILAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. THAILAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 201. VIETNAM SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. VIETNAM SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 203. VIETNAM SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. DENMARK SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 219. DENMARK SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. DENMARK SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 221. DENMARK SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. EGYPT SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. EGYPT SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. EGYPT SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 229. EGYPT SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. FINLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. FINLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. FINLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 237. FINLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 242. FRANCE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. FRANCE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. FRANCE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 245. FRANCE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 250. GERMANY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 251. GERMANY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. GERMANY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 253. GERMANY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. ISRAEL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. ISRAEL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. ISRAEL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 261. ISRAEL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. ITALY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. ITALY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. ITALY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 269. ITALY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 274. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 277. NETHERLANDS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 282. NIGERIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 283. NIGERIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. NIGERIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 285. NIGERIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 290. NORWAY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. NORWAY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. NORWAY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 293. NORWAY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. POLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. POLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. POLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 301. POLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. QATAR SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 303. QATAR SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. QATAR SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 305. QATAR SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 306. QATAR SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. QATAR SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. QATAR SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 309. QATAR SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 310. RUSSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 311. RUSSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 312. RUSSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 313. RUSSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 314. RUSSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 315. RUSSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 316. RUSSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 317. RUSSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 320. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 322. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 323. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 324. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 325. SAUDI ARABIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 326. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 328. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 330. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 332. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. SPAIN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 335. SPAIN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 336. SPAIN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 337. SPAIN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 338. SPAIN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 339. SPAIN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 340. SPAIN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 341. SPAIN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 342. SWEDEN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 343. SWEDEN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 344. SWEDEN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 345. SWEDEN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 346. SWEDEN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 347. SWEDEN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 348. SWEDEN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 349. SWEDEN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 350. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 352. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 353. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 354. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 355. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 356. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 357. SWITZERLAND SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 358. TURKEY SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 359. TURKEY SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 360. TURKEY SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 361. TURKEY SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 362. TURKEY SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 363. TURKEY SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 364. TURKEY SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2030 (USD MILLION)
  • TABLE 365. TURKEY SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED ARAB EMIRATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD MILLION)

TABL